Pieris and Servier, an independent international pharmaceutical company headquartered in France with annual sales of more than EUR4 billion, to jointly pursue several bispecific therapeutic programs including Pieris’ proprietary dual checkpoint inhibitor PRS-332 Alliance includes four additional bispecific programs and may be expanded to a total of eight immuno-oncology programs ; Pieris has option to co-develop and retain US rights for 4 of these programs, including PRS-332 Pieris to receive EUR30 million upfront, up to EUR324 million in success-based payments for PRS-332, up to EUR193 million in success-based payments for each of the other programs and up to double-digit royalties Pieris will host an investor conference call on Thursday, January 5, 2017 at 8:30 AM to discuss the collaboration : PIRS ) , a clinical-stage biotechnology company advancing novel biotherapeutics through its … (more)
Category: Biotech
ContraFect to Present at Biotech Showcase 2017 Conference
The focus of the presentation will be on ContraFect’s lysin technology and its lead program, CF-301, the company’s novel approach to the treatment of drug-resistant Staphylococcus aureus infections, including MRSA. The presentation will be available as a webcast for a limited time.
East/West CEO Conference to Feature Prominent CEOs and Industry Leaders on January 7th & 8th
Join Deborah Dunsire,CEO, Southern Cross Biotech Consulting;Tom Heyman,CEO, Janssen Pharmaceutica;Charlotte Hubbert,Partner, Bill & Melinda Gates Foundation;Emil Kakkis,CEO & President, Ultragenyx;Mathai Mammen,SVP Research, Merck;Geoff McDonough,President & CEO, Sobi;Susan Molineaux,President & CEO, Calithera;Paris Panayiotopoulos,President & CEO, ARIAD;Rob Perez,Founder and Chairman, Life Science Cares;David Pyott,Former CEO, Allergan;Paul Stoffels,CSO, Johnson & Johnson;Henri Termeer, former CEO,Genzyme;J.
Market Sees Rise in Performance Anxiety
After some weak action to end 2016, market players were caught by surprise with a big gap-up open to start the new year. There was a little selling into the strength but then a very strong PMI report gave the bulls another reason to put money to work.
Amgen Hikes Dividend By 15%. Is It A Buy, Sell, Or Hold?
Early in the year, I said that Amgen’s dividend growth is likely to slow down . Specifically, this was my reasoning: Amgen has expanded its payout ratio from 7% in 2011 to 40% now.
Neogen Corporation (NEOG) Position Decreased by Rehmann Capital Advisory Group
Rehmann Capital Advisory Group reduced its position in shares of Neogen Corporation by 0.4% during the third quarter, according to its most recent filing with the Securities and Exchange Commission . The fund owned 3,882 shares of the company’s stock after selling 17 shares during the period.
UMass partners for better biotech
Now, the university’s program will get even stronger as it joins a public-private partnership to develop new advanced manufacturing technologies and train a skilled workforce. Massachusetts has been named a partner in the nation’s first manufacturing innovation institute in biopharmaceutical manufacturing, and UMass Lowell is one of five universities supporting the effort — working towards finding better ways to produce biotech drugs.
Fortress Biotech Announces Publication on MB – 101 (IL13R 2 -…
Fortress Biotech Announces Publication on MB-101 for the Treatment of Glioblastoma in New England Journal of Medicine NEW YORK, Dec. 28, 2016 — Fortress Biotech, Inc. , a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, today announced that a patient case study from the Phase 1 clinical trial of MB-101 for the treatment of glioblastoma will be published in the December 29 edition of the New England Journal of Medicine. MB-101 is the lead development candidate of Mustang Bio, Inc., a Fortress Company.
Press release distribution, EDGAR filing, XBRL, regulatory filings
After many years serving in d… )–Opus Bank announced today that it completed on December 23, 2016 the securitization of approximately $509 million of its multifamily loans th… )–ALS and AD bioinformatics reports confirm GM6’s role as regulator of disease-relevant pathways.
Bill fast-tracked to attract LakePharma
The bill , filed just earlier this month, emerged Tuesday morning from the House Ways and Means Committee and was whisked through the House by noon. Senate Majority Leader Harriette Chandler, D-Worcester, said she hoped to shepherd the bill through the Senate on Tuesday.
Press release distribution, EDGAR filing, XBRL, regulatory filings
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Alexion Pharmaceuticals, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2017 )–Levi & Korsinsky reminds shareholders of a class action lawsuit on behalf of shareholders of Alexion Pharmaceuticals, Inc. who purchased shares between February 10, 2014 … SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of TerraVia Holdings, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2017 )–Levi & Korsinsky reminds shareholders of a class action lawsuit on behalf of shareholders of TerraVia Holdings, Inc. who purchased shares between August 8,… DPLO SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Diplomat Pharmacy, Inc. and a Lead Plaintiff Deadline of January 9, 2017 )–The Law Offices of Vincent Wong … (more)
Press release distribution, EDGAR filing, XBRL, regulatory filings
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Alexion Pharmaceuticals, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2017 )–Levi & Korsinsky reminds shareholders of a class action lawsuit on behalf of shareholders of Alexion Pharmaceuticals, Inc. who purchased shares between February 10, 2014 … SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of TerraVia Holdings, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2017 )–Levi & Korsinsky reminds shareholders of a class action lawsuit on behalf of shareholders of TerraVia Holdings, Inc. who purchased shares between August 8,… DPLO SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Diplomat Pharmacy, Inc. and a Lead Plaintiff Deadline of January 9, 2017 )–The Law Offices of Vincent Wong … (more)
Health Care Companies Showing Good Defensive Potential
Among U.S. companies, health care companies offer good defensive-investing opportunities. Such companies, including Johnson & Johnson , Biogen Inc. and VCA Inc. , generally had strong financial strength and gross margins.
Artificial kidney called ‘holy grail’
A video emerged on Tuesday night of Michael Floyd’s DUI arrest in Arizona from last week.
Neogen Corp. (NEOG) Posts Earnings Results, Beats Expectations By $0.02 EPS
Neogen Corp. released its earnings results on Wednesday. The company reported $0.29 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.27 by $0.02.
Neogen Corp. (NEOG) Posts Earnings Results, Beats Expectations By $0.02 EPS
Neogen Corp. released its earnings results on Wednesday. The company reported $0.29 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.27 by $0.02.
Bristol-Myers Squibb and Calithera Biosciences Announce Clinical…
Bristol-Myers Squibb Company and Calithera Biosciences , Inc. , a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, today announced a clinical trial collaboration to evaluate Bristol-Myers Squibb’s Opdivo in combination with Calithera’s CB-839 in patients with clear cell renal cell carcinoma . CB-839 is an orally administered glutaminase inhibitor currently in Phase 1/2 clinical studies.
Shionogi And Purdue Pharma L.P. Establish Alliance For Joint U.S. Commercialization Of Naldemedine
OSAKA, Japan & STAMFORD, Conn.– — Shionogi & Co., Ltd. , a drug-discovery based pharmaceutical company dedicated to developing medicines that protect the health and well-being of patients, and its wholly-owned U.S. subsidiary, Shionogi Inc. , and Purdue Pharma L.P. , a privately-held pharmaceutical company founded by physicians over 60 years ago, distinguished by its pioneering research, products and medical programs directed toward alleviating pain, today announced the establishment of an alliance for the joint U.S. launch and commercialization of SymproicA .
Merck Wins Record $2.5 Billion Patent Verdict Against Gilead
Gilead Sciences Inc. was told by a federal jury to pay $2.54 billion to Merck & Co. for using a patented invention as the basis for its blockbuster drugs for the potentially deadly liver disease hepatitis C — the biggest patent-infringement verdict in U.S. history.
Oncolytics Biotech Inc. Announces 2016 Year-End Results
“Through this process, and with the help of our expanding senior team, we thoughtfully and deliberately put in place a plan that initially contemplates combinations with chemotherapy for late-stage clinical development, but will expand to include targeted immunotherapies over the longer term as we look to leverage the role of the immune system in patient treatment. In the coming months we will specifically define our first registration pathway.